Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
Does CorMedix (CRMD) Have the Potential to Rally 135.51% as Wall Street Analysts Expect?
10:55am, Thursday, 02'nd May 2024
The mean of analysts' price targets for CorMedix (CRMD) points to a 135.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath
08:30am, Friday, 19'th Apr 2024
BERKELEY HEIGHTS, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
12:54pm, Monday, 15'th Apr 2024
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)
08:30am, Monday, 15'th Apr 2024
BERKELEY HEIGHTS, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
10:55am, Thursday, 11'th Apr 2024
The mean of analysts' price targets for CorMedix (CRMD) points to a 146.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference
08:30am, Thursday, 11'th Apr 2024
BERKELEY HEIGHTS, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and condit
CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC
08:30am, Monday, 08'th Apr 2024
BERKELEY HEIGHTS, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and condit
CorMedix (CRMD) Q4 2023 Earnings Call Transcript
11:17am, Tuesday, 12'th Mar 2024
CorMedix Inc. (NASDAQ:CRMD ) Q4 2023 Earnings Conference Call March 12, 2024 8:30 AM ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice President, Chief Financia
CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07:30am, Tuesday, 12'th Mar 2024
BERKELEY HEIGHTS, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a
CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024
08:30am, Wednesday, 06'th Mar 2024
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a
CorMedix Inc. Announces Commercial and Reimbursement Updates
08:30am, Tuesday, 30'th Jan 2024
BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an
CorMedix Inc. Announces Commercial and Operational Updates
08:30am, Monday, 08'th Jan 2024
BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an
CorMedix Inc. Announces Appointment of Chief Legal Officer
08:30am, Friday, 15'th Dec 2023
BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an
CorMedix Inc. Announces Partnership With The Leapfrog Group
08:30am, Monday, 04'th Dec 2023
– CorMedix to advocate for patient safety and infection prevention as part of Leapfrog's Partners Advisory Committee
– First and only FDA-approved antimicrobial catheter lock solution in the U.S. – Company expects DefenCath to be available in Q1 2024 in the inpatient setting BERKELEY HEIGHTS, N.J., Nov. 15, 2023
